✦ LIBER ✦

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

✍ Scribed by Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri

Book ID: 117307254
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 239 KB
Volume: 377
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)61354-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety profile of belimumab: pooled data

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

✍ Wallace, D.; Navarra, S.; Petri, M.; Gallacher, A.; Thomas, M.; Furie, R.; Levy, 📂 Article 📅 2012 🏛 SAGE Publications 🌐 English ⚖ 138 KB

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

✍ Wallace, Daniel J. ;Stohl, William ;Furie, Richard A. ;Lisse, Jeffrey R. ;McKay, 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 2 views

## Abstract ## Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). ## Methods Patients with a Safety of Estrogens in Lupus Erythematosus: National

A phase III, randomized, placebo-control

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

✍ Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J. Wallace; D 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 684 KB

Biologic activity and safety of belimuma

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

✍ Richard Furie, William Stohl, Ellen M Ginzler… 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 914 KB

Efficacy and safety of tocilizumab in pa

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

✍ Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Sh 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 225 KB

Efficacy and safety of rituximab in mode

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

✍ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p